Search

Displaying results 2141 - 2150 of 4600 in total
  1. Drug

    Felodipine

    go.drugbank.com/drugs/DB01023
    Approved

    It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction.

  2. Drug

    Cyclosporine

    go.drugbank.com/drugs/DB00091
    ApprovedInvestigationalVet approved

    [A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]

  3. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

  4. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    [L40298] In September 2022, Skysona was approved by the FDA.[L43247] … [A243691] Elivaldogene autotemcel works by delivering genes into the patient's body to produce functional ALDPs.

  5. Drug

    Entecavir

    go.drugbank.com/drugs/DB00442
    ApprovedInvestigational

    It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.

  6. Drug

    Quinacrine

    go.drugbank.com/drugs/DB01103
    Investigational

    An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.

  7. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.

  8. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.

  9. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371] … One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO

  10. Drug

    Tavaborole

    go.drugbank.com/drugs/DB09041
    Approved

    Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).